Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients.
about
Quantitative biomarker analysis of synovial gene expression by real-time PCRDifferential clinical efficacy of anti-CD4 monoclonal antibodies in rat adjuvant arthritis is paralleled by differential influence on NF-kappaB binding activity and TNF-alpha secretion of T cellsTregalizumab - A Monoclonal Antibody to Target Regulatory T CellsModulation of IL-17 and Foxp3 expression in the prevention of autoimmune arthritis in miceDemyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessmentsRecent developments in the immunobiology of rheumatoid arthritisNovel human antibody therapeutics: the age of the Umabs.Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies.Protective versus pathogenic anti-CD4 immunity: insights from the study of natural resistance to HIV infection.Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease.New targets of therapy in T-cell lymphomas.Pharmacotherapy: concepts of pathogenesis and emerging treatments. Co-stimulation and T cells as therapeutic targets.A Proteomic Survey Indicates Sortilin as a Secondary Substrate of the ER Translocation Inhibitor Cyclotriazadisulfonamide (CADA).Use of two-dimensional gel electrophoresis to measure changes in synovial fluid proteins from patients with rheumatoid arthritis treated with antibody to CD4.Mechanistic modeling of antigen sink effect for mavrilimumab following intravenous administration in patients with rheumatoid arthritis.Pulmonary pharmacodynamics of an anti-GM-CSFRα antibody enables therapeutic dosing that limits exposure in the lung.Deciphering the In Vivo Performance of a Monoclonal Antibody to Neutralize Its Soluble Target at the Site of Action in a Mouse Collagen-Induced Arthritis Model.
P2860
Q24795033-713C74DE-4A20-4318-9EDB-3CEFFE429E06Q24807250-663400AB-69B0-4A2A-8A8B-876867CD2369Q26772699-3F57064E-C321-4CB8-B09A-F928A17008D4Q30982756-36FACC73-A7E9-472E-871C-E80CDC072F7EQ34395739-F29669C4-A112-4A2B-B93C-4F750100D05CQ35840838-BF72A408-12F4-4A5E-B441-A1D0E5764196Q36757047-347A1AF9-334A-4EC2-9E92-CA7E756F8BE1Q37243228-05F26381-0BC2-483B-91A6-28E1BC983821Q37331009-262D3753-B88C-4AFC-8994-DB0C6534F0B9Q37460580-1365FDBC-BEA5-4DCF-8787-3DCC54407754Q37635011-D9C95385-4E94-4B7A-B331-437C36748961Q37701472-4CE8D2F6-DDF4-4473-9136-C511DFB3B97FQ37781913-B83359EF-1F1E-4AE6-8FA5-DE6B711DA5DFQ38725180-C7C6C404-033F-4A8D-AC0B-1DD139FB9D00Q39507830-3F971838-3D79-4FB4-B6D8-C7B2943A74B9Q39704084-DCD529C1-2CDA-4A8B-9F91-0CB526259A18Q41416064-353A62BE-E612-445D-AB5E-D5EC40449338Q53224491-9BB3FF74-A204-4903-AD92-97F1D6EBC64F
P2860
Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Pharmacokinetic, pharmacodynam ...... rheumatoid arthritis patients.
@en
Pharmacokinetic, pharmacodynam ...... rheumatoid arthritis patients.
@nl
type
label
Pharmacokinetic, pharmacodynam ...... rheumatoid arthritis patients.
@en
Pharmacokinetic, pharmacodynam ...... rheumatoid arthritis patients.
@nl
prefLabel
Pharmacokinetic, pharmacodynam ...... rheumatoid arthritis patients.
@en
Pharmacokinetic, pharmacodynam ...... rheumatoid arthritis patients.
@nl
P2093
P2860
P356
P1433
P1476
Pharmacokinetic, pharmacodynam ...... rheumatoid arthritis patients.
@en
P2093
Connolly DJ
Johnston JM
Kingsley GH
P2860
P304
P356
10.1093/RHEUMATOLOGY/39.10.1139
P577
2000-10-01T00:00:00Z